Brief: TCR2 Therapeutics Qtrly Loss Per Share $0.46

TCR2 Therapeutics

08/08/2019 12:15

Aug 8 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR2 THERAPEUTICS INC - IND FILING FOR TC-110 IN PATIENTS
WITH
CD19+ NON-HODGKIN LYMPHOMA OR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
ANTICIPATED IN 2H19
    * TCR2 THERAPEUTICS INC - ENDED Q2 WITH $180.7 MILLION IN
CASH,
CASH EQUIVALENTS, AND INVESTMENTS VERSUS $123.2 MILLION AS OF
DEC 31, 2018; CASH RUNWAY INTO 2022
    * TCR2 THERAPEUTICS INC SEES INTERIM UPDATE ON TC-210 PHASE
1/2
TRIAL FOR PATIENTS WITH MESOTHELIN-EXPRESSING SOLID TUMORS IN
4Q19/1Q20
    * TCR2 THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.46

Source text for Eikon:  ID:nGNX8WJPX4 
Further company coverage:  TCRR.O 

 ((Reuters.Briefs@thomsonreuters.com;))